Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
29.94
Oct 02 • 3:59 PM ET Dollar change-0.57 Percentage change(-1.87%)
Aftermarket Close
30.03
Aftermarket • 7:59 PM ET Dollar change+0.09 Percentage change(0.30%)
Index
-
Market Cap
3.81B
Enterprise Value
3.31B
Income
-534.80M
Sales
0.00M
Book/sh
3.50
Cash/sh
3.94
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
53
IPO
Apr 29, 2015
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
8.55
P/C
7.59
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
4.72
Current Ratio
4.72
Debt/Eq
0.01
LT Debt/Eq
0.01
Option/Short
Yes / Yes
EPS (ttm)
-4.66
EPS next Y
-4.39
EPS next Q
-1.07
EPS this Y
-44.59%
EPS next Y
4.79%
EPS next 5Y
-3.63%
EPS past 3/5Y
-52.71% -42.46%
Sales past 3/5Y
- -
EPS Y/Y TTM
-203.77%
Sales Y/Y TTM
-
EPS Q/Q
-88.32%
Sales Q/Q
-
Insider Own
3.19%
Insider Trans
-4.43%
Inst Own
59.50%
Inst Trans
1.96%
ROA
-79.24%
ROE
-88.85%
ROIC
-129.73%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-8.93%
SMA50
-10.21%
SMA200
-9.73%
Trades
Shs Outstand
127.17M
Shs Float
123.11M
52W High
43.15 -30.61%
52W Low
25.77 16.18%
Volatility
6.29% 6.34%
ATR (14)
2.59
RSI (14)
42.06
Beta
0.75
Rel Volume
1.66
Avg Volume
3.82M
Volume
6,367,090
Perf Week
-15.80%
Perf Month
-10.63%
Perf Quarter
-22.66%
Perf Half Y
-13.97%
Perf YTD
-14.89%
Perf Year
7.39%
Perf 3Y
175.44%
Perf 5Y
387.62%
Perf 10Y
2036.89%
Prev Close
30.51
Price
29.94
Change %
-1.87%
Date Action Analyst Rating Change Price Target Change
May-28-26Initiated Lake Street Buy $89
May-27-26Resumed Truist Buy $83
Mar-26-26Initiated Wolfe Research Peer Perform
Oct-29-25Initiated Canaccord Genuity Buy $106
Apr-29-25Initiated Cantor Fitzgerald Overweight $104
Apr-08-25Initiated Goldman Neutral $30
Feb-13-25Initiated Scotiabank Sector Outperform $102
Feb-07-25Initiated Citigroup Neutral $38
Dec-02-24Initiated Piper Sandler Overweight
Nov-22-24Initiated B. Riley Securities Buy $109
Sep-28-26 11:29PM
11:02PM
04:30PM
Sep-24-26 01:48PM
10:24AM
08:51AM Loading…
08:51AM
07:05AM
04:25AM
Sep-23-26 10:24PM
06:56PM
04:32PM
08:38AM
08:30AM
08:28AM
07:37AM
07:00AM Loading…
07:00AM
01:45AM
Sep-22-26 10:22PM
10:18PM
05:35PM
05:26PM
04:34PM
04:31PM
04:26PM
03:53PM
02:51PM
01:14PM
12:10PM
11:46AM
11:24AM
11:05AM Loading…
11:05AM
10:40AM
10:24AM
10:07AM
09:49AM
09:39AM
09:07AM
08:22AM
08:08AM
07:05AM
04:32AM
01:29AM
Sep-15-26 02:03AM
Sep-02-26 04:05PM
Aug-31-26 08:23PM
Jul-30-26 01:00PM
03:22AM
01:03AM
Jul-29-26 07:58PM
04:05PM
Jul-23-26 07:05AM
Jul-22-26 04:05PM
Jul-21-26 09:00AM
Jul-17-26 06:39AM
Jul-15-26 08:45AM
Jul-08-26 01:11AM
Jun-25-26 12:14AM
Jun-24-26 02:57PM
07:05AM
Jun-23-26 07:46PM
Jun-11-26 07:05AM
Jun-02-26 07:43PM
May-28-26 09:47AM
May-12-26 07:05AM
May-05-26 07:05AM
Apr-30-26 03:16AM
Apr-29-26 04:05PM
Apr-22-26 04:35PM
Apr-14-26 08:21PM
Apr-10-26 07:30AM
Mar-26-26 07:05AM
Mar-10-26 02:32PM
08:03AM
Mar-09-26 09:05AM
Mar-05-26 05:45PM
04:03PM
08:12AM
Mar-04-26 01:45AM
Mar-02-26 08:50AM
Feb-27-26 05:45PM
Feb-25-26 08:40AM
Feb-24-26 12:00PM
10:17AM
Feb-23-26 04:11PM
02:29PM
01:39PM
Feb-18-26 07:22AM
Feb-17-26 11:04AM
Feb-16-26 10:26AM
09:40AM
Feb-13-26 11:26AM
Feb-12-26 11:31AM
10:07AM
08:42AM
08:30AM
08:03AM
12:03AM
Feb-11-26 06:02PM
05:13PM
04:33PM
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
PresidentDr. Brian Lian Ph.D.
Chief Financial OfficerMr. Gregory S. Zante CPA
Vice President of Finance & AdministrationMr. Michael Morneau
Vice President of Quality & ComplianceMs. Katherine Mercier
Senior Vice President of CommercialMr. Kenneth J. Herman M.B.A.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lian BrianPresident & CEOJul 29 '26Sale33.32148,5174,947,8882,572,441Jul 29 08:07 PM
ZANTE GREGChief Financial OfficerJul 29 '26Sale33.4721,217710,141212,204Jul 29 08:06 PM
Mancini MariannaChief Operating OfficerJul 29 '26Sale33.4718,217609,636422,760Jul 29 08:06 PM
BRIAN LIANOfficerJul 29 '26Proposed Sale33.32148,5174,947,888Jul 29 04:18 PM
GREG ZANTEOfficerJul 29 '26Proposed Sale33.4721,217710,141Jul 29 04:04 PM
MARIANNA MANCINIOfficerJul 29 '26Proposed Sale33.4718,217609,636Jul 29 04:03 PM
Aubuchon Neil WilliamChief Commercial OfficerMar 10 '26Buy33.504,475149,9124,475Mar 10 06:20 PM
ZANTE GREGChief Financial OfficerJan 05 '26Sale32.9057,6611,896,969189,891Jan 05 08:31 PM
Mancini MariannaChief Operating OfficerJan 05 '26Sale32.9857,6611,901,405409,190Jan 05 08:31 PM
Lian BrianPresident & CEOJan 05 '26Sale32.96233,4097,692,1212,499,291Jan 05 08:28 PM
FOEHR MATTHEW WDirectorJan 02 '26Option Exercise3.3316,00053,280148,036Jan 05 08:25 PM
FOEHR MATTHEW WDirectorJan 02 '26Sale35.1116,000561,694132,036Jan 05 08:25 PM
MARIANNA MANCINIOfficerJan 05 '26Proposed Sale32.9857,6611,901,406Jan 05 04:32 PM
GREG ZANTEOfficerJan 05 '26Proposed Sale32.9857,6611,901,470Jan 05 04:30 PM
BRIAN LIANOfficerJan 05 '26Proposed Sale32.96233,4097,692,134Jan 05 04:29 PM
MATTHEW W. FOEHRDirectorJan 02 '26Proposed Sale35.1116,000561,694Jan 02 04:46 PM
Mancini MariannaChief Operating OfficerOct 28 '25Sale35.006,185216,492382,467Oct 28 07:51 PM
Rowland Charles A JrDirectorOct 27 '25Sale35.5760,0002,134,27830,000Oct 28 07:49 PM
Lian BrianPresident & CEOOct 28 '25Sale35.0138,9891,364,9232,419,109Oct 28 07:48 PM
ZANTE GREGChief Financial OfficerOct 28 '25Sale35.006,185216,481173,592Oct 28 07:47 PM
GREG ZANTEOfficerOct 28 '25Proposed Sale35.016,185216,531Oct 28 04:34 PM
MARIANNA MANCINIOfficerOct 28 '25Proposed Sale35.006,185216,492Oct 28 04:32 PM
BRIAN LIANOfficerOct 28 '25Proposed Sale35.0138,9891,364,923Oct 28 04:27 PM
CHARLES A ROWLAND JR.DirectorOct 27 '25Proposed Sale35.5760,0002,134,278Oct 27 04:25 PM